CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Insite Vision Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Insite Vision Inc.
965 ATLANTIC AVE
Phone: (510) 865-8800p:510 865-8800 ALAMEDA, CA  94501  United States Fax: (510) 865-5700f:510 865-5700
This company was Merged or Acquired on 11/3/2015.
This company ceased filing statements with the SEC on 11/2/2015.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
InSite Vision Incorporated is an ophthalmic product development company that offers ophthalmic pharmaceutical products. The Company's portfolio of products is based on its DuraSite sustained drug delivery technology. The Company's offerings include BromSite and DexaSite. DuraSite sustained drug delivery technology is a synthetic polymer-based formulation to extend the residence time of a drug relative to conventional topical therapies. DuraSite enables topical delivery of a drug as a solution, gel or suspension and can be customized for delivering a variety of drug candidates. The Company is engaged in the research and development and commercial support with the DuraSite drug delivery technology for the following topical products: AzaSite, Besivance, BromSite, DexaSite, AzaSite Plus and ISV-101.
(Source: 10-Q)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201512/31/2014YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board TimothyMcInerney 54 12/19/2011 9/23/2008
Chief Executive Officer, Director Timothy M.Ruane 50 12/1/2010 12/1/2010
Chief Financial Officer, Vice President Louis C.Drapeau 70 11/30/2010 10/1/2007
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Azithromycin Royalty Sub, LLC
InSite Vision, Ltd.
Ophthalmic Solutions, Inc.

General Information
Number of Employees: 29 (As of 12/31/2014)
Outstanding Shares: 131,951,033 (As of 8/10/2015)
Shareholders: 149
Stock Exchange: OTC
Federal Tax Id: 943015807
Fax Number: (510) 865-5700
Email Address: insitemail@insite.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023